Analysis: U.S. FDA faces mounting criticism over Alzheimer’s drug approval

In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. The Biogen Inc (BIIB.O) drug, Aduhelm, […]